I
233.87
3.42 (1.48%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Insulet Corporation | Bullish | Bearish |
Stockmoo Score
0.0
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fil Ltd | 30 Jun 2024 | 1,401,704 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 250.00 (BTIG, 6.90%) | Buy |
| Median | 228.50 (-2.30%) | |
| Low | 220.00 (Barclays, -5.93%) | Hold |
| Average | 231.75 (-0.91%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 187.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 12 Aug 2024 | 220.00 (-5.93%) | Hold | 188.05 |
| BTIG | 09 Aug 2024 | 250.00 (6.90%) | Buy | 182.19 |
| UBS | 09 Aug 2024 | 223.00 (-4.65%) | Hold | 182.19 |
| Canaccord Genuity | 23 Jul 2024 | 234.00 (0.06%) | Buy | 196.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |